Dr. Falk Pharma’s norucholic acid (NCA) drug has demonstrated potential in a Phase III trial for primary sclerosing ...

Morningstar brands and products Company Portfolio ...

There is currently no approved medicine to treat primary sclerosing cholangitis ... and no worsening of disease stage on histology was achieved by a statistically significantly greater proportion ...

Study results demonstrate superiority of norucholic acid (NCA) over placebo in the combined primary endpoint. There is ...

Falk Pharma’s norucholic acid (NCA) drug has demonstrated potential in a Phase III trial for primary sclerosing cholangitis (PSC ... of disease stage on histology. Significant superiority ...

Dr Falk Pharma, a research-based pharmaceutical company specialising in digestive and metabolic medicine, has announced ...

The presentation will be available on the Rectify website at https://rectifypharma.com/publications/.